The number of coaches actively earning at Medifast fell 47.7%, to 10,200.
Medifast reported a 47.7% drop in active earning coaches to 10,200, with Q3 2026 revenue at $72.0M. Net loss was $2.1M, with adjusted net loss at $17.5M. CEO Nick Johnson highlighted improved coach productivity and plans for Q4 profitability. The company expects Q4 revenue between $70M and $75M. Medifast's balance sheet remains strong with $172.5M in cash and no debt.
How this was made
The 30-second read
Why it matters
The earnings miss and modest guidance could trigger short‑term downside, but the announced strategic initiatives may offer longer‑term upside.
Market read
First‑time disclosure of Q3 financials and Q4 guidance for Medifast, providing fresh data for traders.
What to watch
Potential upside from upcoming product Reset Fueling launch and cost‑saving Catalyst program.
Background
Medifast (NYSE:MED) released its unaudited Q3 2026 earnings, highlighting a decline in active coaches and a net loss, while outlining its 3.0 strategy execution.
Ticker impact
Q3 2026 results show revenue of $72.0 M and a non‑GAAP net loss of $17.5 M, with guidance for Q4 revenue range disclosed.
likely pressure as the market prices in the loss and modest revenue guidance
The disclosed loss and lack of strong guidance typically trigger a sell‑off in the short term.
Market effects
Weight‑loss and metabolic‑health sector may see broader scrutiny as Medifast reports weaker profitability.
U.S. consumer‑health stocks could face modest pullback.
Limited; primarily affects U.S. health‑and‑wellness equities.
Counterpoint
If the new compensation plan drives coach productivity, the loss could be temporary and the stock may rebound.
Key entities
- ExecutiveNick Johnson
CEO of Medifast, provided commentary on Q3 performance and future outlook.
